LFCR Stock Forecast & Price Target

Lifecore Biomedical is benefiting from a clear turnaround in which CEO Paul Josephs has built a stronger leadership team, reduced expenses, and shifted the company into an execution phase focused on late-stage and commercial site-transfer wins. The pipeline now exceeds 30 active projects, including over a dozen late-stage or commercial transfers, with the late-stage/site-transfer opportunity estimated at more than $100 million annualized unweighted and over $50 million weighted, while the recent seven additions over seven months should materially expand future revenue. Despite leverage of $184 million in debt, nearly $50 million in convertible preferred stock, and only $17.5 million in cash, affirmed guidance for over $10 million in free cash flow in 2026 and a path to over $200 million in revenue by 2029 supports a positive outlook driven by rising utilization from 20% toward approximately 60%.

Lifecore Biomedical is facing a negative outlook because its valuation is dependent on EV/EBITDA while the company may fail to meet revenue or earnings estimates, creating meaningful execution risk. As a CDMO with revenue tied to both complex sterile injectable services and HA manufacturing, the business is exposed to demand variability and operational setbacks that could undermine expected profitability. The repeated warning that target outcomes may not be achieved highlights uncertainty around financial performance, suggesting the stock remains vulnerable if growth or margin assumptions prove too optimistic.